Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.

NCT03476109 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Severe Asthma

Interventions

DRUG: Randomisation to omalizumab
DRUG: Randomisation to mepolizumab

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]